Jessica Garcia
Sugar Land, TXNPI 1275310492
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 66.0% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $9,117 and has fallen 71.6% since, to $2,591 in 2025.
Across 192 payments — averaging $72.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$9K
- AbbVie$1K
- UCB, Inc.$621
- Neurocrine Biosciences, Inc.$545
- Eisai Inc.$484
- Lilly USA, LLC$387
- plus $2K from 25 others
What the payments were for
- Consulting fees$8,13059%
- Travel & lodging$9477%
- Food & beverage$4,78635%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 6 | $9,143 |
| AbbVie | 49 | $1,067 |
| UCB, Inc. | 20 | $621 |
| Neurocrine Biosciences, Inc. | 18 | $545 |
| Eisai Inc. | 17 | $484 |
| Lilly USA, LLC | 18 | $387 |
| Novartis | 12 | $251 |
| Otsuka America Pharmaceutical, Inc. | 11 | $245 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| SK Life Science, Inc. | 1 | $99 |
| Merz Pharmaceuticals, LLC | 3 | $87 |
| Johnson & Johnson | 3 | $78 |
| Acadia Pharmaceuticals Inc | 4 | $78 |
| Pfizer | 4 | $78 |
| Amneal Pharmaceuticals LLC | 3 | $68 |
| Biogen | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Neurelis, Inc. | 1 | $46 |
| Impel Pharmaceuticals LLC | 2 | $45 |
| EMD Serono, Inc. | 2 | $37 |
| Azurity Pharmaceuticals, Inc. | 2 | $36 |
| Scilex Pharmaceuticals Inc. | 2 | $35 |
| Lundbeck LLC | 1 | $34 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Integra Lifesciences Corporation | 1 | $29 |
| Grifols USA, LLC | 1 | $23 |
| Acorda Therapeutics, Inc | 1 | $21 |
| Life Molecular Imaging Ltd | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| AstraZeneca | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbamazepine ErCarbamazepine | 15 | $2,465 |
| Memantine Hcl | 77 | $2,386 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 34 | $1,387 |
| Gabapentin | 45 | $644 |
| Topiramate | 30 | $525 |
| Escitalopram Oxalate | 24 | $447 |
| Donepezil Hcl | 58 | $375 |
| Mirtazapine | 14 | $327 |
| Duloxetine Hcl | 14 | $304 |
| RizatriptanRizatriptan Benzoate | 15 | $291 |
| Prednisone | 14 | $22 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.